Effi cacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): An international, multicentre, randomised, placebo-controlled, phase 3 trial

The Lancet

Volumn 381, Issue 9863, 2013, Pages 295-302

  Demetri, George D ^a   Reichardt, Peter ^b   Kang, Yoon Koo ^c   Blay, Jean Yves ^d   Rutkowski, Piotr ^e   Gelderblom, Hans ^f   Hohenberger, Peter ^g   Leahy, Michael ^h   Von Mehren, Margaret ⁱ   Joensuu, Heikki ^j   Badalamenti, Giuseppe ^k   Blackstein, Martin ^l   Le Cesne, Axel ^m   Ski, Patrick Schöff ⁿ   Maki, Robert G ^o   Bauer, Sebastian ^p   Nguyen, Binh Bui ^q   Xu, Jianming ^r   Nishida, Toshirou ^s   Chung, John ^t   Kappeler, Christian ^u   Kuss, Iris ^v   Laurent, Dirk ^a   Casali, Paolo G ^a   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HELIOS Klinikum Bad Saarow   (Germany)

^c University of Ulsan   (South Korea)

^d UNIVERSITÉ LYON 1   (France)

^e INSTITUTE OF ONCOLOGY   (Poland)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF HEIDELBERG   (Germany)

^h CHRISTIE HOSPITAL   (United Kingdom)

ⁱ FOX CHASE CANCER CENTER   (United States)

^j UNIVERSITY OF HELSINKI   (Finland)

^k UNIVERSITY OF PALERMO   (Italy)

^l MOUNT SINAI HOSPITAL   (Canada)

^m INSTITUT GUSTAVE ROUSSY   (France)

ⁿ UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^o MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^p UNIVERSITY HOSPITAL ESSEN   (Germany)

^q INSTITUT BERGONIÉ   (France)

^r BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^s OSAKA POLICE HOSPITAL   (Japan)

^t BAYER CORPORATION   (United States)

^u BAYER PHARMA AG   (Germany)

^v NATIONAL CANCER INSTITUTE   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PLACEBO; REGORAFENIB; SUNITINIB; 4 (4 (((4 CHLORO 3 (TRIFLUOROMETHYL)PHENYL)CARBAMOYL)AMINO) 3 FLUOROPHENOXY) N METHYLPYRIDINE 2 CARBOXAMIDE; 4-(4-(((4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)CARBAMOYL)AMINO)-3-FLUOROPHENOXY)-N-METHYLPYRIDINE-2-CARBOXAMIDE; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; INDOLE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DYSPHONIA; FATIGUE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SYNDROME; HOARSENESS; HUMAN; HYPERTENSION; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; ORAL MUCOSITIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; CONTROLLED CLINICAL TRIAL; GASTROINTESTINAL TUMOR; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL RATE; TREATMENT FAILURE;

AGED; ANTINEOPLASTIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; MALE; MIDDLE AGED; PHENYLUREA COMPOUNDS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRIMIDINES; PYRROLES; SURVIVAL RATE; TREATMENT FAILURE;

MLCS; MLOWN;

EID: 84872892692     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)61857-1     Document Type: Article

References (33)

1. Demetri GD, von Mehren M, Antonescu CR, et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw 2010; 8: S1-41.
2. Joensuu H. Adjuvant treatment of GIST: patient selection and treatment strategies. Nat Rev Clin Oncol 2012; 9: 351-58.
3. Edmonson JH, Marks RS, Buckner JC, Mahoney MR. Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Cancer Invest 2002; 20: 605-12.
4. Dematteo RP, Heinrich MC, El-Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 2002; 33: 466-77.
5. Caram MV, Schuetze SM. Advanced or metastatic gastrointestinal stromal tumors: systemic treatment options. J Surg Oncol 2011; 104: 888-95.
6. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21: 4342-49.
7. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-80.
8. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299: 708-10.
9. Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer 2011; 11: 865-78.
10. Demetri GD, von Mehren M, Blanke CD, et al. Effi cacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-80.
11. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364: 1127-34.
12. Dematteo RP, Ballman KV, Antonescu CR, et al, on behalf of the American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373: 1097-104.
13. Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 2012; 307: 1265-72.
14. Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase 3 Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008; 26: 5360-67.
15. Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006; 42: 1093-103.
16. Antonescu CR, Besmer P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005; 11: 4182-90.
17. Chen LL, Trent JC, Wu EF, et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 2004; 64: 5913-19.
18. Debiec-Rychter M, Cools J, Dumez H, et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 2005; 128: 270-79.
19. Liegl B, Kepten I, Le C, et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol 2008; 216: 64-74.
20. Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006; 24: 4764-74.
21. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003; 2: 471-78.
22. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-37.
23. O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101: 3597-605.
24. Osusky KL, Hallahan DE, Fu A, Ye F, Shyr Y, Geng L. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little eff ect on existing tumor vessels. Angiogenesis 2004; 7: 225-33.
25. Broutin S, Ameur N, Lacroix L, et al. Identifi cation of soluble candidate biomarkers of therapeutic response to sunitinib in medullary thyroid carcinoma in preclinical models. Clin Cancer Res 2011; 17: 2044-54.
26. Demetri GD, van Oosterom AT, Garrett CR, et al. Effi cacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368: 1329-38.
27. Gajiwala KS, Wu JC, Christensen J, et al. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci USA 2009; 106: 1542-47.
28. Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 2011; 129: 245-55.
29. Mross K, Frost A, Steinbild S, et al. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res 2012; 18: 2658-67.
30. George S, Wang Q, Heinrich MC, et al. Effi cacy and safety of regorafenib in patients with metastatic and/or uresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol 2012; 30: 2401-07.
31. Ducimetière F, Lurkin A, Ranchère-Vince D, et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS One 2011; 6: e20294.
32. Demetri GD. Diff erential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors. Semin Oncol 2011; 38 (suppl 1): S10-19.
33. Reichardt P, Blay JY, Gelderblom H, et al. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Ann Oncol 2012; 23: 1680-87.